U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07017231) titled 'Role of Interleukin-13 Pathways on Pain and Itch Sensitivity ( IL-13 )' on May 30.
Brief Summary: Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in people with atopic dermatitis.
Study Start Date: May 15
Study Type: INTERVENTIONA...